STO · FLUI.ST
Fluicell AB (publ)
SEK 27.70+SEK 0.00 (0.0%)
Fluicell AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 58.78% below the high.
Loading market information…
STO · S2M.ST · SEK
Stock price, earnings
Quote as of Oct 30, 2026, 08:07 AM UTC. Cached market data; not a live quote.
One-year closing-price history · SEK. Historical prices are not a forecast.
S2Medical AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 76.0% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow S2Medical AB (publ)’s reporting calendar.
THE COMPANY BEHIND THE TICKER
S2Medical AB (publ) focuses on the development, production, and commercialization of advanced wound care solutions, specifically targeting burns and chronic wounds. Their product range features INSTAQRETT, a sterile, disposable tool for mechanical debridement; EPIPROTECT SafeStop, designed to control bleeding; and Instagraft, a single-use medical device for treating complex and prolonged wounds. The company also supplies EPIPROTECT tissue replacement products and INSTABIND-branded bandages, which are known for being washable, waterproof, and self-adhesive. Furthermore, S2Medical distributes Silverlon dressings, which facilitate the delivery of silver ions to the wound. In addition to its product offerings, the company operates specialized wound healing centers known as S2Clinic. Founded in 2013, S2Medical is headquartered in Linköping, Sweden.
Latest available per-share figures in SEK. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 08:09 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
SEK 27.70+SEK 0.00 (0.0%)
Fluicell AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 58.78% below the high.
SEK 0.01+SEK 0.00 (+6.98%)
Spermosens AB’s quoted price sits in the upper half of its reported 52-week range, 23.33% below the high.
SEK 1.33-SEK 0.04 (-2.92%)
ODI Pharma AB’s quoted price sits in the lower half of its reported 52-week range, 75.6% below the high.
SEK 0.02+SEK 0.01 (+36.26%)
Gabather AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 75.2% below the high.
SEK 0.21SEK 0.00 (0.0%)
Stayble Therapeutics AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 68.27% below the high.
SEK 0.11-SEK 0.00 (-0.93%)
Prostatype Genomics AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 95.35% below the high.
SEK 0.02SEK 0.00 (0.0%)
LIDDS AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 87.7% below the high.
SEK 0.00-SEK 0.00 (-16.67%)
Quia Pharma AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 98.33% below the high.
